department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Linagliptin + Metformin Hydrochloride · pharmadog

pharmadog
drugs
Linagliptin + Metformin Hydrochloride

drug

patient view →

(linagliptin + metformin hydrochloride)

Marketedupdated 2mo ago

by MSN Pharmaceuticals Inc

Approved

community read0 votes

indications

investigational

Type 2 Diabetes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Linagliptin + Metformin Hydrochloride

generic

(linagliptin + metformin hydrochloride)

indication

Type 2 Diabetes

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 36m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Dec 20, 2026

163 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (30)

Dec 8, 2037patentUS 12364700*PED
Dec 8, 2037patentUS 12364700*PED
Jun 8, 2037method-of-use (U-4224)US 12364700
Jun 8, 2037method-of-use (U-4224)US 12364700
Sep 6, 2033patentUS 9555001*PED
Sep 6, 2033patentUS 9555001*PED
Mar 6, 2033formulationUS 9555001
Mar 6, 2033formulationUS 9555001
Nov 21, 2030patentUS 9155705*PED4.4y
Nov 21, 2030patentUS 9155705*PED4.4y
May 21, 2030formulationUS 91557053.9y
May 21, 2030formulationUS 91557053.9y
Apr 10, 2030method-of-use (U-3854)US 119113883.8y
Apr 10, 2030method-of-use (U-3854)US 119113883.8y
Oct 2, 2029patentUS 10022379*PED3.2y
Oct 2, 2029patentUS 10022379*PED3.2y
Oct 2, 2029patentUS 9415016*PED3.2y
Oct 2, 2029patentUS 9415016*PED3.2y
Apr 2, 2029method-of-use (U-2339)US 100223792.7y
Apr 2, 2029method-of-use (U-2339)US 100223792.7y
Apr 2, 2029formulationUS 94150162.7y
Apr 2, 2029formulationUS 94150162.7y
Nov 4, 2027patentUS 8673927*PED1.3y
Nov 4, 2027patentUS 8673927*PED1.3y
Nov 4, 2027patentUS 9173859*PED1.3y
Nov 4, 2027patentUS 9173859*PED1.3y
May 26, 2026patentUS 8883805*PED
May 26, 2026patentUS 8883805*PED
Nov 26, 2025formulationUS 8883805
Nov 26, 2025formulationUS 8883805

FDA exclusivities (4)

Dec 20, 2026PEDPediatric (6mo bonus)163d
Dec 20, 2026PEDPediatric (6mo bonus)163d
Jun 20, 2026M-295Method (3y)
Jun 20, 2026M-295Method (3y)

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?